Interferón para la esclerosis múltiple recurrente‐remitente
Información
- DOI:
- https://doi.org/10.1002/14651858.CD002002Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 23 octubre 2001see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Esclerosis múltiple y enfermedades raras del sistema nervioso central
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Prof G PA Rice and Dr G Filippini conceived the idea and development of the project, posed the questions of the research project, designed the protocol, appraised the relevance and the validity of the papers and co‐ordinated the review. G Rice abstracted data and wrote to sponsors of trials for additional information. They both analyzed the results and wrote the text of the review.
Dr B Incorvaia and Dr L Munari: They both were involved in the search strategy, abstracted data and helped in the analysis of the results and writing of the test of the review. Dr B Incorvaia organized retrieval of papers.
Prof Chris Polman: Assisted in the design of the protocol, abstracted data, assisted in data interpretation and reviewed the manuscript drafts.
Dr R D'Amico assisted in statistical analysis and writing of the test of the review.
Prof George Ebers: Assisted in the design of the protocol, data interpretation and reviewed the manuscript drafts.
Dr E Parmelli collaborated to the update of the review.
Sources of support
Internal sources
-
Department of Clinical Neurological Sciences, University of Western Ontario, Canada.
-
National Neurological Institute C. Besta, Milan, Italy.
External sources
-
Multiple Sclerosis Society of Canada (applied), Canada.
-
Fondazione Italiana Sclerosi Multipla, Italy.
Declarations of interest
The review was assembled, analysed and reported independent from any pharmaceutical company input.
Prof Rice has participated in clinical trials sponsored by SCHERING, SERONO, BERLEX, BIOGEN, and TEVA. He has received honoraria from these companies.
Prof Ebers has received honoraria for lectures found to be sponsored by relevant companies and has been an investigator for several clinical trials in multiple sclerosis including three interferon studies involving SCHERING, SERONO funding. He does not feel his opinions (which are largely critical of the efficacy of interferons) are influenced by these associations.
Prof Polman has received honoraria for lecturing, consultancy from companies producing interferon beta.
Dr Filippini has received travel expenses from Farmades pharmaceutical company for participating at neurological conferences.
Drs Munari, D'Amico, Incorvaia and Parmelli have no conflict of interest.
Acknowledgements
Authors wish to thank Prof Jon Deeks (Centre for Statistics in Medicine, Institute of Health Sciences, Oxford UK ), Prof Alessandro Liberati and Ms Elena Telaro (Italian Cochrane Centre), Dr Bernard MJ Uitdehaag (VU Medical Centre, Amsterdam, The Netherlands), Prof Silvio Garattini and Dr Walter Torri (Istituto di Ricerche "Mario Negri", Milan Italy), Prof Alan Thompson (Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, UK), Prof Silvana Simi, Prof Daniela Lupo and Mr Lorenzo Brait (participant consumers of the Cochrane MS Group) for useful comments during the preparation of the manuscript.
Version history
| Published | Title | Stage | Authors | Version |
| 2001 Oct 23 | Interferon in relapsing‐remitting multiple sclerosis | Review | George PA Rice, Barbara Incorvaia, Luca M. Munari, George Ebers, Chris Polman, Roberto D'Amico, Elena Parmelli, Graziella Filippini | |
